Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3944]

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC...

Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot

Challenging the status quo: Unlocking new horizons for patients with HR-NMIBC after BCG treatment ( Prof Bernardo Hererra Imbroda and Dr Géraldine Pignot )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Dr Jean Abraham - University of Cambridge, Cambridge, UK

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer ( Dr Jean Abraham - University of Cambridge, Cambridge, UK )

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

Dr Ricky Frazer and Dr Sree Subramanian

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective ( Dr Ricky Frazer and Dr Sree Subramanian )

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid...

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )

More from ecancer